How effective is larotrectinib against untargeted targets?

Larotrectinib (Larotrectinib) is a targeted therapy drug mainly used for cancer patients carrying NTRK (neuronal growth factor receptor kinase) gene fusion. However, the therapeutic effect of larotrectinib is relatively limited for tumors without NTRK gene fusions.

In clinical trials and research, the efficacy of larotrectinib is mainly reflected in its ability to inhibit the growth of cancer caused byNTRK gene fusion. NTRKgene fusion is a relatively rare but important oncogenic mechanism in some cancers, so larotrectinib significantly improves the treatment outcomes of patients carrying NTRKgene fusion by specifically interfering with this target.

However, larotrectinib is relatively less effective in tumors withoutNTRK gene fusions. Because it is specifically designed to target tumors with NTRK gene fusions, larotrectinib is not a preferred treatment option for other tumor types. In these cases, clinicians often choose other treatments that are appropriate for the specific tumor type, such as chemotherapy, radiation therapy, or other targeted therapies.

Larotrectinib has been launched in China and has not yet been included in medical insurance. Since it has not been launched in China for a long time, it may be difficult to purchase it in hospitals. For specific conditions, it is recommended to consult the local hospital pharmacy. In foreign markets, larotinib has two options: original drug and generic drug. Original drugs include the German version, the American version, the European version and the Hong Kong version, and the price is about 10,000 to 20,000 yuan. In comparison, generic drugs are much cheaper. There are Lao and Bangladeshi versions of generic drugs, and the price is around two to three thousand. It is worth noting that the ingredients of original drugs and generic drugs are basically the same.